Vascular Biogenics Ltd. (VBLT) Trading 7.4% Higher
Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price traded up 7.4% during mid-day trading on Wednesday . The company traded as high as $4.37 and last traded at $4.23, with a volume of 542,679 shares. The stock had previously closed at $3.94.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Roth Capital reiterated a “buy” rating and set a $22.00 target price on shares of Vascular Biogenics in a research report on Thursday, June 9th. HC Wainwright assumed coverage on shares of Vascular Biogenics in a research report on Tuesday, June 28th. They set a “buy” rating and a $11.00 target price on the stock. Chardan Capital reiterated a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $14.00 target price on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $16.50.
The firm’s 50-day moving average is $4.12 and its 200 day moving average is $3.63. The firm’s market cap is $95.52 million.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Equities research analysts predict that Vascular Biogenics Ltd. will post ($0.82) EPS for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.